Table of Contents
- Basic Information & Specifications
- Mechanism of Action
- Clinical Applications
- Antibiotic Combinations
- Dosage Guidelines
- Clinical Case Studies
- Global Suppliers
- Contact for Technical Inquiry
Basic Information & Specifications
| Parameter | Value |
|---|---|
| CAS Number | 68373-14-8 |
| Molecular Formula | C₈H₁₁NO₅S |
| Molecular Weight | 233.24 g/mol |
| Appearance | White to off-white crystalline powder |
| Solubility | Freely soluble in water (100 mg/mL) |
| Storage | 2-8°C protected from light |
| Manufacturer | Entasis Therapeutics (US), CSPC Pharmaceutical (China) |
Mechanism of Action
As an irreversible β-lactamase inhibitor, sulbactam:
- Inhibits Ambler Class A serine β-lactamases through covalent binding
- Enhances antibiotic activity of β-lactams by 4-64 fold against resistant strains
- Displays intrinsic bactericidal activity against Acinetobacter baumannii via PBP1/PBP3 inhibition
Clinical Applications
FDA-approved indications (Xacduro® 2023):
| Infection Type | Pathogen Coverage |
|---|---|
| Hospital-acquired pneumonia | Acinetobacter calcoaceticus-baumannii complex |
| Ventilator-associated pneumonia | Carbapenem-resistant Acinetobacter spp. |
Antibiotic Combinations
| Combination | Ratio | Spectrum |
|---|---|---|
| Ampicillin/Sulbactam | 2:1 | Gram-negative bacilli, anaerobes |
| Cefoperazone/Sulbactam | 1:1 | ESBL-producing Enterobacteriaceae |
| Sulbactam/Durlobactam | 2:1 | Multidrug-resistant Acinetobacter |
Dosage Guidelines
| Renal Function (CrCl) | Dosing Interval |
|---|---|
| >45 mL/min | 1g q6h |
| 30-44 mL/min | 1g q8h |
| 15-29 mL/min | 1g q12h |
| Hemodialysis | Post-dialysis administration required |
Clinical Case Studies
- Case 1: 62-year-old male with VAP caused by CRAB showed 92% clinical cure rate with sulbactam-durlobactam combination therapy (7-day course)
- Case 2: ICU outbreak of NDM-1 Klebsiella pneumoniae controlled using cefoperazone/sulbactam 3g q8h (MIC reduction from 32 μg/mL to 2 μg/mL)
Global Suppliers
| Manufacturer | Location | Certifications |
|---|---|---|
| Pfizer | USA | USP, cGMP |
| Qilu Pharmaceutical | China | EDQM, WHO PQ |
Contact for Technical Inquiry
For formulation support or clinical protocol development:
Email: info@vivalr.com
Tel: (86) 15866781826



评论
目前还没有评论。